Tianhong Li, M.D., Ph.D.
Professor, Department of Internal Medicine, Division of Hematology and Oncology
To see if Tianhong Li is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).
Locations and Contact
UC Davis Comprehensive Cancer Center
UC Davis Comprehensive Cancer Center
4501 X St.
Sacramento, CA 95817
Additional Numbers
Clinic Phone
Clinic Fax
Clinic Referral Phone
Physician Referrals
Philosophy of Care
Dr. Li sees each patient is unique and would like to support her patients through the journey fighting cancer. Dr. Li believes in a multidisciplinary team approach to provide the best cancer care to individual patients. She provides her patients the most state-of-the-art cancer care, including the option of participating in promising clinical trials.
Clinical Interests
Dr. Li is a board-certified, practicing medical oncologist specialized in experimental therapeutics focusing on lung cancer and breast cancer at the UC Davis Comprehensive Cancer Center (UCDCCC). She also attends lung cancer clinic at VA Northern California Health Care System (VANCHCS).
Research/Academic Interests
Dr. Li is interested in personalized cancer care by applying her extensive laboratory and clinical research knowledge. Her career goal is to translate innovative treatment strategies and technology advances into direct patient care through early phase clinical trials. Her current research focuses on understanding the primary and acquired resistance mechanisms of cancer therapy and improving tissue and blood-based molecular and immune biomarkers for precision lung cancer therapy.
Division
Hematology and Oncology
Center/Program Affiliation
Medical School
M.D., Beijing University School of Medicine, Beijing, China 1989
Other School
Ph.D., Microbiology and Immunology, Loyola University, Stritch School of Medicine, Maywood IL 1996
Internship
Internal Medicine, Beth Israel Medical Center, Albert Einstein College of Medicine, New York NY 1997-1998
Residency
Internal Medicine, Beth Israel Medical Center, Albert Einstein College of Medicine, New York NY 1998-2000
Fellowship
Hematology/Oncology, Montefiore Medical Center, Albert Einstein College or Medicine, Bronx NY 2003
VA Merit Award, 2021, 2022, 2023, 2024, 2025
Top Doctors in Hematology and Oncology, Sacramento Magazine, 2020
First Prize Poster Award, the 17th Annual Cancer Research Symposium, UCD Cancer Center, 2013
K12 Scholar, Clinical and Translational Science Center (CTSC), UC Davis School of Medicine, Sacramento CA, 2009, 2010, 2011, 2012
Young Investigator Award, Southwest Oncology Group (SWOG), The Hope Foundation, Seattle WA, 2010
To view a detailed list of Dr. Li's publications, please click here.
Ma W, Zeng J, Chen S, Lyu Y, Toomey KA, Phan CT, Yoneda KY, Li T. Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC. Biomark Res. 2021 Sep 6;9(1):69. doi:10.1186/s40364-021-00324-6. PMID:34488906
Li Q, Ma W, Chen S, Tian EC, Wei S, Fan RR, Wang T, Zhou C, Li T. High integrin α3 expression is associated with poor prognosis in patients with non-small cell lung cancer. Transl Lung Cancer Res. 2020 Aug;9(4):1361-1378. doi:10.21037/tlcr-19-633. PMID:32953510.
Xiao W, Ma W, Wei S, Li Q, Liu R, Carney RP, Yang K, Lee J, Nyugen A, Yoneda KY, Lam KS, Li T. High-affinity peptide ligand LXY30 for targeting α3β1 integrin in non-small cell lung cancer. J Hematol Oncol. 2019 Jun 10;12(1):56. doi:10.1186/s13045-019-0740-7. Erratum in: J Hematol Oncol. 2019 Jul 26;12(1):83. PMID:31182116.
Gregg JP, Li T, Yoneda KY. Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey. Transl Lung Cancer Res. 2019 Jun;8(3):286-301. doi:10.21037/tlcr.2019.04.14. PMID:31367542.
Li T, Piperdi B, Walsh WV, Kim M, Beckett LA, Gucalp R, Haigentz M Jr, Bathini VG, Wen H, Zhou K, Pasquinelli PB, Gajavelli S, Sreedhara M, Xie X, Lara PN Jr, Gandara DR, Perez-Soler R. Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer. Clin Lung Cancer. 2017 Jan;18(1):60-67. doi:10.1016/j.cllc.2016.10.003. Epub 2016 Oct 28. PMID:27919627.
Ma W, Gilligan BM, Yuan J, Li T. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol. 2016 May 27;9(1):47. doi:10.1186/s13045-016-0277-y. PMID:27234522.
Li T, LoRusso P, Maitland ML, Ou SH, Bahceci E, Ball HA, Park JW, Yuen G, Tolcher A. First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors. J Hematol Oncol. 2016 Mar 10;9:23. doi:10.1186/s13045-016-0254-5. PMID:26966027.
Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol. 2013 Mar 10;31(8):1039-49. doi:10.1200/JCO.2012.45.3753. Epub 2013 Feb 11. PMID:23401433.
Li T, Guo M, Gradishar WJ, Sparano JA, Perez EA, Wang M, Sledge GW. A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103). Breast Cancer Res Treat. 2012 Jul;134(1):345-52. doi:10.1007/s10549-012-2071-z. Epub 2012 May 1. PMID:22547107.